Related Experiment Videos
Prolonged bleeding time associated with moxalactam administration
Neurosurgery
|June 1, 1984
Abstract:
A case of moxalactam-induced coagulopathy is reported. The authors think that this coagulopathy is caused by an effect on platelet aggregation and not by inhibition of vitamin K-dependent clotting factors. It is recommended that bleeding times be routinely checked preoperatively in patients being treated with moxalactam.
Insights
Moxalactam can cause bleeding problems by affecting platelet aggregation, not vitamin K clotting factors. Routine preoperative bleeding time tests are recommended for patients on moxalactam.
Area of Science:
- Pharmacology
- Hematology
Background:
- Moxalactam is a broad-spectrum antibiotic.
- Coagulopathy is a condition affecting blood clotting.
Observation:
- A patient developed coagulopathy while being treated with moxalactam.
Findings:
- The coagulopathy was attributed to an effect on platelet aggregation.
- Moxalactam did not appear to inhibit vitamin K-dependent clotting factors.
Implications:
- Preoperative bleeding time assessment is crucial for patients receiving moxalactam.
- Understanding moxalactam's mechanism of coagulopathy aids in patient management.